We are live on ! Find out more

886 hedge funds and large institutions have $17.8B invested in Biogen in 2025 Q1 according to their latest regulatory filings, with 106 funds opening new positions, 334 increasing their positions, 275 reducing their positions, and 108 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 334 | Existing positions reduced: 275

1% more funds holding

Funds holding: 879 → 886 (+7)

2% less first-time investments, than exits

New positions opened: 106 | Existing positions closed: 108

1.97% less ownership

Funds ownership: 90.76% → 88.78% (-2%)

22% less capital inflows, than outflows

Capital inflows: $1.47B | Capital outflows: $1.87B

44% less call options, than puts

Call options by funds: $345M | Put options by funds: $621M

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

Holders
886
Holders Change
+7
Holders Change %
+0.8%
% of All Funds
11.83%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
106
Increased
334
Reduced
275
Closed
108
Calls
$345​M
Puts
$621​M
Net Calls
-⁠$276​M
Net Calls Change
-⁠$230​M

BIIB Hedge Fund Activity: Q1 2025 in Review

886 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2025, worth a combined $17.8B — down 12% from $20.2B a quarter earlier.

Sellers outnumbered buyers: 108 funds closed out of BIIB and 106 opened new positions — a net loss of 2 holders — while 275 trimmed existing stakes and 334 added.

The largest buyer was AQR Capital Management, adding an estimated $119M. The largest seller was Beutel, Goodman & Co, cutting an estimated $250M.

  • 886 institutional investors held Biogen (BIIB) as of Q1 2025, up from 879 in Q4 2024.
  • Funds reported $17.8B of Biogen stock for Q1 2025, down 12% quarter-over-quarter.
  • 106 funds opened new Biogen positions in Q1 2025 and 108 closed out, a net change of -2 holders.
  • The largest Biogen buyer in Q1 2025 was AQR Capital Management, an estimated $119M added.
  • The largest Biogen seller in Q1 2025 was Beutel, Goodman & Co, an estimated $250M sold.

Based on aggregated 13F filings for Q1 2025.